Aerovate To Go Ex-Dividend On April 29th, 2025 With 2.4 USD Dividend Per Share
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences; Board Approves 1-for-35 Reverse Stock Split
Express News | Aerovate Therapeutics Inc - Board Approves 1-for-35 Reverse Stock Split
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals >AVTE
Aerovate Therapeutics Declares Special Cash Dividend Of $69.6M, Or An Estimated $2.40 Per Share
Aerovate Therapeutics: Cash Div Expected to Be in the Range of $67.6M-$69.6M >AVTE
Express News | Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection With the Proposed Merger With Jade Biosciences
Press Release: Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection With the Proposed Merger With Jade Biosciences
Aerovate | 10-K: FY2024 Annual Report
Aerovate Therapeutics Reports Q3 Loss Amid Strategic Shift
Aerovate | 10-Q: Q3 2024 Earnings Report
Calendar of U.S. Earnings Expected in the Week Ahead
M&A Deals Roundup: AbbVie, Blackstone, Take-Two Interactive and More
12 Health Care Stocks Moving In Thursday's Intraday Session
Express News | Aerovate Therapeutics - Upon Termination of Deal Under Specified Circumstances, Co May Be Required to Pay Jade Termination Fee of $2.3 Mln
Express News | Aerovate Therapeutics - Exchange Ratio Assumes Valuation for Aerovate of $8.0 Million and Valuation for Jade of $175.0 Mln
Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Trading Halt: Halt Status Updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times